|  |
| --- |
| September 5, 2013 |
|  |
| Tim Lange  Head of Investor Relations  Phone +49 201 177-3150  tim.lange@evonik.com |
|  |
| Evonik Industries AG  Rellinghauser Straße 1-11  45128 Essen Germany  Phone +49 201 177-01  Telefax +49 201 177-3475  www.evonik.de  **Supervisory Board**  Dr. Werner Müller, Chairman  Executive Board  Dr. Klaus Engel, Chairman  Dr. Wolfgang Colberg, Dr. Thomas Haeberle,  Thomas Wessel, Patrik Wohlhauser, Dr. Dahai Yu  Registered office Essen  Registered court  Essen local court  Commercial registry B 19474  VAT ID no. DE 811160003 |

**Evonik promoted to MDAX**

Shares of the specialty chemicals company Evonik Industries AG will join the MDAX effective September 23, 2013. This was announced by Deutsche Börse AG yesterday evening. The MDAX share index comprises the shares of Germany’s 50 largest listed companies, following those of the DAX, in terms of market capitalization and trading volume.

Evonik’s CEO, Dr. Klaus Engel, comments: “Evonik’s upgrade to the MDAX just months after our initial share listing on April 25, 2013 reflects the high level of interest generated among investors. Inclusion in the MDAX will mean greater visibility for Evonik on the international financial markets. For the future, that gives us even more motivation to continue tight adherence to our corporate strategy and its key elements of profitable growth, efficiency and values.”

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders   
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6 billion and an operating profit (adjusted EBITDA) of about €2.6 billion.

**Disclaimer**

In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.